• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Prenosis, Roche Partner to Combat Hospital Sepsis Using Precision Diagnostics

by Jasmine Pennic 10/14/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Prenosis Inc., a precision diagnostics company transforming clinical diagnosis with artificial intelligence, announced today the expansion of an existing partnership with Roche Diagnostics that will total close to $6 million to improve and expedite the clinical recognition of sepsis.

– Building upon the collaboration that the companies started together in 2020, Prenosis will significantly expand its core NOSIS™ dataset, and the two companies will work together to obtain U.S. Food and Drug Administration (FDA) clearance for the Prenosis Sepsis Immunoscore™ and the Roche Elecsys® IL-6 Assay.  These tools aim to provide physicians with powerful new solutions for fighting sepsis through early risk identification.

Impact of Sepsis

According to the World Health Organization, more than 11 million people die from sepsis worldwide annually, more than the deaths caused by all cancers combined.  Studies show that sepsis is the leading cause of death in U.S. hospitals, with total annual costs of treatment and rehabilitation estimated at $62 billion. Before the COVID-19 pandemic, at least 1.7 million adults in the United States developed sepsis annually.  During the pandemic, this problem was greatly exacerbated, as most COVID-19 deaths are due to viral and/or bacterial sepsis.

Early prediction of at-risk patients that require emergency department evaluation and hospitalization can dramatically improve outcomes. Combining routinely obtained clinical information with additional critical biomarkers could help identify at-risk patients earlier and more accurately for life-saving treatment.

Prenosis Dataset

The Prenosis dataset, which features Elecsys IL-6 measurements, in addition to measurements of a diverse set of parameters representing several different dimensions of immune response, is the world’s largest and fastest growing hybrid biomarker-clinical dataset for sepsis care.  The partnership drives the unique combination of a traditional diagnostic test with next-generation predictive analytics, demonstrating the potential to usher in a new era of holistic digital diagnostics for more comprehensive profiling of complex heterogeneous hospital conditions.

The Roche Elecsys® IL-6 assay measures interleukin-6 concentrations from patient plasma or serum samples. Elecsys IL-6 is a predictive biomarker essential in the disease pathways of many inflammatory conditions, including sepsis thanks to its early elevation. The Elecsys IL6 results can be provided in 18 minutes. The Prenosis Sepsis Immunoscore™ diagnostic utilizes the combination of Elecsys IL-6 with other sepsis biomarkers and distinct clinical risk parameters and aims to predict, diagnose and treat sepsis earlier.

“We are excited to expand upon our relationship with Roche and to accelerate the birth of ‘prenostic’ testing to help reduce the burden of the sepsis crisis,” said Prenosis CEO and Co-Founder Bobby Reddy, Jr.  “Prenostics, or predictive and precise diagnostics, test the right patient parameters at the right time for the right clinical situation/context. The Prenosis platform is ushering in a new era in pre-emptive diagnostic testing. The implications are groundbreaking: we have the ability to accurately and cost-effectively predict disease much earlier, enabling prevention instead of treatment.”

The Sepsis ImmunoScore™ is an Artificial Intelligence/Machine Learning (AI/ML) Software as a Medical Device (SaMD) that Prenosis intends to submit to the FDA for clearance by the end of the year. It is intended to aid in the risk assessment for progression to sepsis of patients admitted to the emergency department or hospital. The solution incorporates holistic, multidimensional inputs using machine learning to more adequately capture the vast heterogeneity of sepsis and to improve the accuracy of diagnosis compared to the current standard of care risk assessments. The solution incorporates 23 parameters from the patient’s hospital Electronic Medical Record (EMR), including demographics, vital signs, labs, and other specific sepsis biomarkers, including Elecsys IL-6.

The diagnostic creates a calculated sepsis risk score, a risk stratification category and other supplemental information that can be visualized in a unique Sepsis Patient View within a hospital Electronic Medical Record or via a web interface. By employing parameters representing many dimensions of information, the Sepsis ImmunoScore™ seeks to more effectively diagnose sepsis and risk stratify patients for care based on severity of illness.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: diagnostic testing, Precision Medicine, Roche, Sepsis

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |